Dianthus Therapeutics (NASDAQ:DNTH) Coverage Initiated at Wells Fargo & Company

Equities research analysts at Wells Fargo & Company started coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research report issued on Thursday, MarketBeat.com reports. The brokerage set an “overweight” rating and a $135.00 price target on the stock. Wells Fargo & Company‘s price target suggests a potential upside of 73.61% from the stock’s previous close.

A number of other research firms have also commented on DNTH. William Blair restated an “outperform” rating on shares of Dianthus Therapeutics in a research report on Monday. Jefferies Financial Group set a $98.00 target price on shares of Dianthus Therapeutics and gave the stock a “buy” rating in a report on Monday, March 9th. Stifel Nicolaus set a $120.00 target price on shares of Dianthus Therapeutics in a research note on Monday, March 9th. Wedbush raised their price target on shares of Dianthus Therapeutics from $55.00 to $80.00 and gave the company an “outperform” rating in a report on Tuesday, March 10th. Finally, Truist Financial boosted their price target on shares of Dianthus Therapeutics from $63.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, March 9th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $117.30.

Dianthus Therapeutics Stock Performance

Shares of DNTH opened at $77.76 on Thursday. Dianthus Therapeutics has a 52-week low of $13.36 and a 52-week high of $88.02. The stock’s 50-day simple moving average is $56.65 and its 200 day simple moving average is $44.46. The stock has a market capitalization of $3.46 billion, a price-to-earnings ratio of -18.97 and a beta of 1.56.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Monday, March 9th. The company reported ($1.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. The company had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $0.40 million. On average, research analysts forecast that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Insider Buying and Selling at Dianthus Therapeutics

In other news, CEO Marino Garcia sold 122,918 shares of the firm’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $81.49, for a total transaction of $10,016,587.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Simrat Randhawa sold 33,830 shares of the firm’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $81.48, for a total value of $2,756,468.40. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 200,430 shares of company stock worth $16,332,702. 8.15% of the stock is owned by insiders.

Institutional Trading of Dianthus Therapeutics

Several institutional investors have recently bought and sold shares of the company. Parkside Financial Bank & Trust increased its stake in Dianthus Therapeutics by 131.7% during the 3rd quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock valued at $37,000 after purchasing an additional 540 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Dianthus Therapeutics in the fourth quarter worth approximately $40,000. Raymond James Financial Inc. purchased a new stake in shares of Dianthus Therapeutics during the second quarter valued at approximately $27,000. Russell Investments Group Ltd. purchased a new stake in shares of Dianthus Therapeutics during the third quarter valued at approximately $64,000. Finally, Royal Bank of Canada increased its position in shares of Dianthus Therapeutics by 36.9% during the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock valued at $82,000 after acquiring an additional 542 shares in the last quarter. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.